Passage Bio Inc. Company Profile
NASDAQ: PASGHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Passage Bio at a glance
Passage Bio Inc. (NASDAQ: PASG) is a Biotechnology company in the Healthcare sector headquartered in Philadelphia, PA. Passage Bio is led by Dr. William Chou M.D., Ph.D. and employs about 24 people. The company's shares have traded publicly since 2020.
At a market capitalization of $12.4 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001787297, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Passage Bio do?
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Passage Bio Inc.
- Ticker
- NASDAQ: PASG
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. William Chou M.D., Ph.D.
- Employees
- 24
- Headquarters
- One Commerce Square, Philadelphia, PA, United States
- Phone
- 267 866 0311
- Website
- passagebio.com
- IPO year
- 2020
- Market cap
- $12.40M
- SEC CIK
- 0001787297
Companies similar to Passage Bio
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LTRNLantern Pharma Inc. | 0.83 | -8.79% | $12.40M | vs PASG |
| PLURPluri Inc. | 1.00 | -3.85% | $12.61M | vs PASG |
| INTSIntensity Therapeutics Inc. | 3.68 | -3.16% | $12.01M | vs PASG |
| LSTALisata Therapeutics Inc. | 1.20 | +2.56% | $12.96M | vs PASG |
| TPSTTempest Therapeutics Inc. | 0.77 | -2.70% | $13.01M | vs PASG |
| CLRBCellectar Biosciences Inc. | 1.40 | -7.28% | $13.23M | vs PASG |
| CTXRCitius Pharmaceuticals Inc. | 0.4887 | -2.47% | $13.42M | vs PASG |
| NIKINiki BioSolutions Inc. | 4.32 | -7.10% | $13.47M | vs PASG |